We are live on ! Find out more
KTTA icon

Pasithea Therapeutics

21 hedge funds and large institutions have $9.5M invested in Pasithea Therapeutics in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

2.19% less ownership

Funds ownership: 57.71% → 55.51% (-2.2%)

19% less funds holding

Funds holding: 26 → 21 (-5)

30% less capital inflows, than outflows

Capital inflows: $1.22M | Capital outflows: $1.75M

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
21
Holders Change
-5
Holders Change %
-19.23%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KTTA Hedge Fund Activity: Q1 2026 in Review

21 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q1 2026, worth a combined $9.5M — down 43% from $16.7M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of KTTA and 1 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 6 added.

The largest buyer was Cable Car Capital, adding an estimated $591K. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $580K sold.

  • 21 institutional investors held Pasithea Therapeutics (KTTA) as of Q1 2026, down from 26 in Q4 2025.
  • Funds reported $9.5M of Pasithea Therapeutics stock for Q1 2026, down 43% quarter-over-quarter.
  • 1 fund opened new Pasithea Therapeutics positions in Q1 2026 and 7 closed out, a net change of -6 holders.
  • The largest Pasithea Therapeutics buyer in Q1 2026 was Cable Car Capital, an estimated $591K added.
  • The largest Pasithea Therapeutics seller in Q1 2026 was Acuta Capital Partners, an estimated $580K sold.

Based on aggregated 13F filings for Q1 2026.